Ning Wu

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Professor

UA Little Rock

Also affiliated: Ithaka Harbors (2013); Tulane University (2017); Biogen (United States) (2016–2018); Beth Israel Deaconess Medical Center (2013); Van Andel Institute (2017–2023); Harvard University (2013); Central South University (2016–2020); Guiyang Medical University (2023); Hunan University of Traditional Chinese Medicine (2020); Shanxi Medical University (2024); Shanghai Jiao Tong University (2016); Regeneron (United States) (2020); Peking University (2025); Huazhong Agricultural University (2014–2016); Renji Hospital (2016); Academy of Military Medical Sciences (2008); United BioSource Corporation (United Kingdom) (2010–2012); Integrated Chinese Medicine (China) (2025); Hanalei Watershed Hui (2011); The People's Hospital of Guangxi Zhuang Autonomous Region (2022–2024); Chongqing University of Education (2020); Dana-Farber Cancer Institute (1984); Peking University First Hospital (2025); Shanghai University of Medicine and Health Sciences (2021–2022); Ministry of Agriculture and Rural Affairs (2014–2016); Dongfeng Motor Group (China) (2018–2020); Center for Systems Biology (2013); Xiangya Hospital Central South University (2016–2020); Shanxi Provincial People’s Hospital (2024); Health & Life (Taiwan) (2010); Institute of Pharmacology (2015–2024); Nanjing Medical University (2013–2016); Tsinghua University (2008)

23 h-index 100 pubs 3,021 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Ning Wu's research focuses on understanding metabolic processes and their links to disease, with a particular emphasis on cellular signaling pathways and the impact of environmental factors. Wu has investigated the role of AMP-activated protein kinase (AMPK) and AKT in regulating glucose uptake through the GLUT1 transporter, as detailed in publications concerning AMPK-dependent degradation of TXNIP and AKT-mediated phosphorylation of TXNIP. Further work explores the therapeutic potential of natural compounds, such as Cyclocarya paliurus polysaccharides, in alleviating type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids.

Wu's research also extends to the effects of environmental stressors on biological systems. Studies have examined heat stress-induced changes in the fecal microbiome and functional pathways of laying hens, as well as the impact of microcystin-LR exposure on hepatic antioxidant responses and reproductive impairment in zebrafish. Additionally, Wu has contributed to research on potential biomarkers for central nervous system diseases and has conducted retrospective cohort studies on treatment compliance in multiple sclerosis patients. Wu leads a research group and has a scholarly profile including an h-index of 23, over 100 publications, and more than 3,000 citations, designating Wu as a highly cited researcher. Collaborations include shared publications with researchers from the National Center for Toxicological Research.

Metrics

h-index: 23
Publications: 100
Citations: 3,021

Positions

Professor publications 2025

University of Arkansas at Little Rock Institution web page

Selected Publications

Interaction-induced knowledge narrowing risk in LLM systems (2026)

Discover Artificial Intelligence DOI OpenAlex
Echo Chamber Dynamics in LLMs: Mitigating Bias and Model Drift (2026)

Communications in computer and information science DOI OpenAlex
AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women (2025)

Experimental Biology and Medicine 58 citations DOI OpenAlex